You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Integrin beta 3 antibody [CRC54] (ab34409)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Integrin beta 3 antibody [CRC54]
See all Integrin beta 3 products (31) ...

Description

Mouse monoclonal [CRC54] to Integrin beta 3

Specificity

The antibody reacts with platelets and megakaryocytes. The antibody reacts preferentially with the activated/occupied form of platelet GPIIb-IIIa (ligand- induced biding site or LIBS epitope) and dissociated form of GPIIIa. This antibody does not react with platelets of patients with Glanzmann thrombastenia.

Tested applications

Flow Cyt, ICC/IF, IHC-Fr, WBmore details

Cross reactivity

Reacts with

Human

Immunogen

Purified human gpIIIa/VNR beta-chain glycoprotein.

Epitope

The epitope is located within the N-terminal region of GPIIIa (first 100 amino acids).

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: Sodium Azide
Constituents: PBS

Concentration

Concentration information loading...

Purity

IgG fraction

Purification notes

Ammonium sulfate + DEAE-cellulose, gradient elution

Clonality

Monoclonal

Clone number

CRC54

Isotype

IgG1

Light chain type

kappa

Applications

Show applications key

Our Abpromise guarantee covers the use of ab34409 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • ShowHide

    Flow Cyt

     Flow Cyt: Use at an assa...Read more →

    Flow Cyt: Use at an assay dependent dilution.

  • ShowHide

    ICC/IF

     ICC/IF: Use at an assay ...Read more →

    ICC/IF: Use at an assay dependent dilution.

  • ShowHide

    IHC-Fr

     IHC-Fr: Use at an assay ...Read more →

    IHC-Fr: Use at an assay dependent dilution.

  • ShowHide

    WB

     WB: Use at an assay depe...Read more →

    WB: Use at an assay dependent dilution. Predicted molecular weight: 87 kDa.

Target

Function

Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Tissue specificity

Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.

Involvement in disease

Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.

Sequence similarities

Belongs to the integrin beta chain family.
Contains 1 VWFA domain.

Post-translational
modifications

Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding.

Cellular localization

Membrane.

Target information above from: UniProt accessionP05106 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • BDPLT2 antibody
  • CD 61 antibody
  • CD61 antibody
  • CD61 antigen antibody
  • GP3A antibody
  • GPIIIa antibody
  • GT antibody
  • HPA 1 antibody
  • HPA 4 antibody
  • Integrin beta 3 (platelet glycoprotein IIIa antigen CD61) antibody
  • Integrin beta chain beta 3 antibody
  • Integrin beta-3 antibody
  • ITB3_HUMAN antibody
  • ITG B3 antibody
  • ITGB 3 antibody
  • ITGB3 antibody
  • NAIT antibody
  • Platelet fibrinogen receptor beta subunit antibody
  • Platelet glycoprotein IIIa antibody
  • platelet glycoprotein IIIa precursor antibody
  • Platelet membrane glycoprotein IIIa antibody
  • PTP antibody
see all

References for Anti-Integrin beta 3 antibody [CRC54] (ab34409)

This product has been referenced in:

  • Alghisi GCet al. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4:e4449 (2009). ICC/IF; Human.Read more (PubMed: 19212436) »
  • Reynolds ARet al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392-400 (2009). Flow Cyt; Human. Read more (PubMed: 19305413) »

See all 3 publications for this product

Publishing research using ab34409? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"